# References

Organized by mechanistic evidence chain (Table 3, SAD v4.0).

---

## Core Mechanism: Statin -> Cholesterol Depletion (Lock 3)

- **Montero et al.** (2008) Elevated mitochondrial cholesterol confers chemotherapy resistance in HCC. *Cancer Research*.
- **Huang et al.** (2024) Lovastatin induces mtDNA release and cGAS-STING activation in HCT116 CRC cells. *Antioxidants (Basel)* 13(6):679.
- **Shen et al.** (2024) Statins specifically reduce mitochondrial membrane cholesterol. *eLife*.
- **Betaneli et al.** (2012) Cholesterol rigidifies the OMM and disfavors VDAC1 oligomeric transitions. *Biophysical Journal*.

## Gate-Opening Physics: VDAC1 Oligomerization

- **Shoshan-Barmatz et al.** (multiple) VDAC1 oligomerization; basis for GJS cofactor equation.
- **Kim et al.** (2019) mtDNA escapes through VDAC1 oligomeric pores. *Science*.

## Innate Immune Ignition: cGAS-STING

- **Li & Chen** (2018) cGAS-STING pathway: cytosolic DNA sensing to type I interferon.
- **West et al.** (2015) mtDNA as endogenous STING ligand.

## Clinical Validation: Statin + ICI

- **Liao et al.** (2025) Meta-analysis (n=46,154): statin + ICI = 20% mortality reduction. *JCO Oncology Practice*.
- **Stokes et al.** (2023) Statins enhance PD-1 blockade via M2->M1 repolarization. *J ImmunoTherapy of Cancer*.

## Cavalry Drug: Botensilimab

- **Vidal et al.** (2024) Botensilimab + balstilimab: 17-20% ORR in MSS CRC. *Nature Medicine*.

## Pathway B: CoQ10 / ROS Amplification

- **Huang et al.** (2024) Lovastatin depletes CoQ10, increases mito ROS. *Antioxidants*.

## TSPO / Fourth Lock (Exploratory)

- **Gatliff et al.** (2014) TSPO physically binds VDAC1 on OMM. *Autophagy*.
- **Maaser et al.** (2002/2005) TSPO overexpression in 28% CRC; prognostic. *Clinical Cancer Research*.
- **Banati et al.** (2014) TSPO-KO mice viable, normal lifespan. *Nature Communications*.
- **Zhang et al.** (2023) PK11195 + anti-PD-1 synergy in HCC. *Advanced Science*.
- **Tu et al.** (2015) PK11195 off-target effects in TSPO-KO. *Endocrinology*.
- **Fu et al.** (2020) TSPO-KD paradoxically promotes glioblastoma growth. *Neuro-Oncology*.

## CBD Quarantine Evidence

- **Sido et al.** (2016) CBD suppresses CD8+ T-cell proliferation at 5-10 uM.
- **Kaplan et al.** (2003) CBD immunosuppressive at VDAC1-active concentrations.
- **ESMO 2024 interim** (NCT03944447) CBD + nivolumab 10.7% ORR in MSS CRC.
- **Ibeas Bih et al.** (2015) CBD affects 65+ molecular targets.
- **Nelson et al.** (2020) CBD colloidal aggregation at >10 uM. *J Medicinal Chemistry*.
- **Bar-Sela et al.** Cannabis users: OS 6.4 vs 28.5 months on immunotherapy.
- **Catherall et al.** (2022) Cholesterol disruption potentiates CBD-induced apoptosis. *MCP*.

## Falsification Sources (Killed Original Hypothesis)

- **Jimenez-Loygorri et al.** (2024) Mitophagy clears mtDNA, doesn't release it. *Nature Communications*.
- **Bakhoum et al.** (2020) Chronic cGAS-STING is immunosuppressive. *Cancer Discovery*.
- **Sliter et al.** (2018) Mitophagy role is clearance.
- **Wang et al.** (2025) Confirms mitophagy clearance role. *Autophagy*.
